Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antibiotic treatment for laryngeal leukoplakia
2020-006011-23Phase 4Active
- Sponsor
- Petra Pietarinen
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cefalexin in laryngitis and Laryngeal leukoplakia, sponsored by Petra Pietarinen. Primary endpoint: Healing of laryngitis and leukoplakia. Started Jan 2021; status: active.
02
Drugs
cefalexin
03
Conditions
laryngitisLaryngeal leukoplakia
Beyond the preview
Go deeper on 2020-006011-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-006011-23.